Table 5.
Previous therapies and course of six patients with grade ≥ 3 hematologic adverse events.
| Patient | Previous Therapies after Castration Resistance |
Toxicity (CTCmax) | Course of Treatment/Disease after RLT | ||
|---|---|---|---|---|---|
| Hb | WBC | Plt | |||
| 1 | ENZA, ABI, 223Ra | 3 | 4 | 4 | transfusion (RBC, BP), PD, death 15 weeks after last cycle |
| 2 | DOCE, ABI, 223Ra | 3 | 4 | 4 | transfusion (RBC, BP), PD, death 18 weeks after last cycle |
| 3 | ABI, 223Ra | 3 | 3 | 4 | transfusion (RBC, BP), PD, death 15 weeks after last cycle |
| 4 | 223Ra | 3 | 3 | 4 | transfusion (RBC, BP), PD, DOCE, death 60 weeks after last cycle |
| 5 | DOCE, ABI, ENZA, 223Ra | 2 | 3 | 3 | transfusion (RBC), PD, death 14 weeks after last cycle |
| 6 | ENZA, 223Ra | 3 | 3 | 2 | transfusion (RBC, BP), PD, Re-ENZA, ABI, death 48 weeks after last cycle |
DOCE: docetaxel, ABI: abiraterone, ENZA: enzalutamide, RBC: packed red blood cells, BP: blood platelet concentrates, Hb: hemoglobin, WBC: white blood cells, Plt: platelets.